Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($4.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.94) by $2.02, Briefing.com reports. The company had revenue of $62.18 million for the quarter, compared to the consensus estimate of $34.60 million. During the same period in the prior year, the firm posted ($5.34) EPS.
Madrigal Pharmaceuticals Price Performance
Shares of NASDAQ MDGL traded up $60.24 during mid-day trading on Friday, hitting $319.58. 2,929,642 shares of the company’s stock traded hands, compared to its average volume of 436,072. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.72 and a quick ratio of 8.67. Madrigal Pharmaceuticals has a 1 year low of $133.99 and a 1 year high of $321.19. The company’s 50-day moving average is $226.07 and its two-hundred day moving average is $242.02. The company has a market capitalization of $6.94 billion, a P/E ratio of -12.43 and a beta of -0.44.
Insider Buying and Selling
In other Madrigal Pharmaceuticals news, CEO William John Sibold sold 6,363 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $243.83, for a total transaction of $1,551,490.29. Following the sale, the chief executive officer now directly owns 55,887 shares in the company, valued at $13,626,927.21. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. 22.80% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
Check Out Our Latest Report on MDGL
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
Further Reading
- Five stocks we like better than Madrigal Pharmaceuticals
- How to Invest in Blue Chip Stocks
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- What Investors Need to Know to Beat the Market
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- How to Buy Cheap Stocks Step by Step
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.